Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
Rhea-AI Summary
Oragenics (NYSE American: OGEN) announced its participation at the Emergencies in Medicine Conference in Park City, Utah from February 23-28, 2025. Dr. James Kelly, Chief Medical Officer, will present on the company's concussion treatment advancements, specifically focusing on their "Trigger-to-Treat" program.
Dr. Kelly's presentation will highlight ONP-002, a novel intranasal neurosteroid for acute concussion treatment. The clinical trials incorporate BRAINBox Solutions' multi-marker, multimodality test that combines blood biomarker technology and neurocognitive testing to improve concussion detection and patient stratification.
Dr. Frank Peacock, Meeting Director and Principal Investigator for both BRAINBox and Oragenics' clinical trials, emphasized that early identification of high-risk patients could accelerate recovery and reduce long-term neurological complications.
Positive
- Oragenics is advancing innovative treatments for concussion with their novel intranasal neurosteroid ONP-002
- The company is integrating cutting-edge diagnostic technology from BRAINBox Solutions into their clinical trials
- The Trigger-to-Treat paradigm represents a significant advancement in acute concussion care
- Presentation at a prestigious medical conference indicates growing interest in their approach
Negative
- No specific data or preliminary results from the clinical trials were mentioned in the press release
- Timeline for potential regulatory approval or market availability of ONP-002 was not provided
- Financial details or funding status for the ongoing clinical trials were not disclosed
- Competitive landscape and differentiation from other concussion treatments not addressed
News Market Reaction – OGEN
In the trading session that priced this news, OGEN gained 0.48%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SARASOTA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced its participation at the Emergencies in Medicine Conference, where Dr. James Kelly, Chief Medical Officer and Oragenics' Medical Advisory Board Member, will present on the advancement of concussion treatments. The event will be held February 23-28, 2025 in Park City, Utah.
Dr. Kelly’s presentation, titled “The Use of a Novel Intranasal Neurosteroid to Treat Concussion Predicted to Have Poor Outcomes,” will focus on Oragenics' "Trigger-to-Treat" program for concussion, specifically highlighting the development of ONP-002, a novel intranasal neurosteroid for the acute treatment of concussion through the subacute period. His session will provide insight into the ongoing clinical trial protocols that incorporate BRAINBox Solutions’ multi-marker, multimodality test incorporating blood biomarker technology and neurocognitive testing a cutting-edge diagnostic platform designed to improve concussion detection, prognosis and patient stratification.
“We are excited to showcase the progress of ONP-002 and our commitment to advancing concussion treatment,” said Dr. Kelly. “By integrating BRAINBox’s cutting-edge platform into our clinical trials, we aim to establish a new standard of care that enables early intervention and more precise treatment strategies. This meeting brings together leading experts in emergency and neurological medicine, and we look forward to discussing how our technology can enhance clinical decision-making and improve patient outcomes in concussion care.”
Dr. Frank Peacock, Meeting Director and Principal Investigator for both the BRAINBox HeadSmart II clinical trials and Oragenics’ ONP-002 clinical trials, comments, “The ‘Trigger-to-Treat’ paradigm marks a significant advancement in acute concussion care. Early identification of high-risk patients and timely intervention have the potential to not only accelerate recovery but also reduce the risk of long-term neurological complications. By improving diagnostic precision and developing targeted treatment strategies, we are taking critical steps toward preventing chronic neurological disease and transforming concussion management.”
The Emergencies in Medicine Conference brings together leading healthcare professionals and researchers to discuss advancements in emergency and trauma care. This event serves as a platform for experts across various fields to explore innovative solutions that improve patient outcomes, with concussion treatment remaining a key area of focus. For more information, please visit https://emergenciesinmedicine.com/.
Investor Contact
Rich Cockrell
404.736.3838
ogen@cg.capital
About Oragenics, Inc.
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, circumstances should change, except as otherwise required by law.
